[1] Yang L, Colditz GA.Prevalence of overweight and obesity in the United States,2007-2012[J]. JAMA Intern Med,2015,175(8):1412-413.
[2] 王增武, 郝光,王馨, 等. 我国中年人群超重/肥胖现况及心血管病危险因素聚集分析[J]. 中华流行病学杂志,2014,35(4):354-358.
[3] Cummings DE, Weigle DS, Frayo RS, et al.Plasma ghrelin levels after diet--induced weight loss or gastric bypass surgery[J]. N Engl J Med,2002,346(21):1623-1630.
[4] Nieben OG, Harboe H.Intragastric balloon as an artificial bezoar for treatment of obesity[J]. Lancet,1982,1(8265):198-199.
[5] Yorke E, Switzer NJ, Reso A, et al.Intragastric balloon for management of severe obesity: a systematic review[J]. Obes Surg,2016,26(9):2248-2254.
[6] Crea N, Pata G, Della Casa D, et al.Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis[J]. Obes Surg,2009,19(8):1084-1088.
[7] Marinos G, Eliades C, Raman Muthusamy V, et al.Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3-and 6-month study[J]. Surg Obes Relat Dis,2014,10(5):929-934.
[8] Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al.Endosco-pic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up[J]. Obes Surg,2017,27(10):2649-2655.
[9] Sharaiha RZ, Kumta NA, Saumoy M, et al.Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients[J]. Clin Gastroenterol Hepatol,2017,15(4):504-510.
[10] Devière J, Ojeda Valdes G, Cuevas Herrera L, et al.Safety, feasibility and weight loss after transoral gastroplasty: first human multicenter study[J]. Surg Endosc,2008,22(3):589-598.
[11] Familiari P, Costamagna G, Bléro D, et al.Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome[J]. Gastrointest Endosc,2011,74(6):1248-1258.
[12] Miller K, Turro R, Greve JW, et al.MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after poseSM vs. medical therapy[J]. Obes Surg,2017,27(2):310-322.
[13] de Jong K, Mathus-Vliegen EM, Veldhuyzen EA, et al. Short-term safety and efficacy of the trans-oral endosco-pic restrictive implant system for the treatment of obesity[J]. Gastrointest Endosc,2010,72(3):497-504.
[14] Verlaan T, Paulus GF, Mathus-Vliegen EM.et al.Endoscopic gastric volume reduction with a novel articulating plication device is safe and effective in the treatment of obesity(with video)[J]. Gastrointest Endosc,2015,81(2):312-320.
[15] Thompson CC, Abu Dayyeh BK, Kushner R, et al.Percutaneous gastrostomy device for the treatment of class Ⅱ and class Ⅲ obesity: results of a randomized controlled trial[J]. Am J Gastroenterol,2017,112(3):447-457.
[16] Sullivan S, Stein R, Jonnalagadda S, et al.Aspiration therapy leads to weight loss in obese subjects: a pilot study[J]. Gastroenterology,2013,145(6):1245-1252.
[17] García-Compean D, Mendoza-Fuerte E, Martínez JA, et al.Endoscopic injection of botulinum toxin in the gastric antrum for the treatment of obesity. Results of a pilot study[J]. Gastroenterol Clin Biol,2005,29(8-9):789-791.
[18] Foschi D, Corsi F, Lazzaroni M, et al.Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study[J]. Int J Obes (Lond),2007,31(4):707-712.
[19] Li L, Liu QS, Liu WH, et al.Treatment of obesity by endoscopic gastric intramural injection of botulinum toxin A: a randomized clinical trial[J]. Hepatogastroenterology,2012,59(118):2003-2007.
[20] Koehestanie P, de Jonge C, Berends FJ, et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter rando-mized controlled trial[J]. Ann Surg,2014,260(6):984-992.
[21] Vilarrasa N, de Gordejuela AG, Casajoana A, et al. Endobarrier® in grade I obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism[J]. Obes Surg,2017,27(3):569-577.
[22] Rajagopalan H, Cherrington AD, Thompson CC, et al.Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study[J]. Diabetes Care,2016,39(12):2254-2261.
[23] Kumbhari V, Lehmann S, Schlichting N, et al.Gastric mucosal devitalization is safe and effective in reducing body weight and visceral adiposity in a porcine model[J]. Gastrointest Endosc,2018,88(1):175-184.
[24] Machytka E, Bužga M, Zonca P, et al.Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes[J]. Gastrointest Endosc,2017,86(5):904-912.
[25] Sandler BJ, Rumbaut R, Swain CP, et al.One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity[J]. Surg Endosc,2015,29(11):3298-3303.
